Alnylam Pharmaceuticals Shares Outstanding 2006-2019 | ALNY

Alnylam Pharmaceuticals shares outstanding history from 2006 to 2019. Shares outstanding can be defined as the number of shares held by shareholders (including insiders) assuming conversion of all convertible debt, securities, warrants and options. This metric excludes the company's treasury shares.
  • Alnylam Pharmaceuticals shares outstanding for the quarter ending March 31, 2019 were 0.105B, a 5.42% increase year-over-year.
  • Alnylam Pharmaceuticals 2018 shares outstanding were 0.101B, a 11.08% increase from 2017.
  • Alnylam Pharmaceuticals 2017 shares outstanding were 0.091B, a 5.79% increase from 2016.
  • Alnylam Pharmaceuticals 2016 shares outstanding were 0.086B, a 1.91% increase from 2015.
Alnylam Pharmaceuticals Annual Shares Outstanding
(Millions of Shares)
2018 101
2017 91
2016 86
2015 84
2014 74
2013 62
2012 50
2011 42
2010 42
2009 42
2008 41
2007 39
2006 32
2005 22
Alnylam Pharmaceuticals Quarterly Shares Outstanding
(Millions of Shares)
Q1 2019 105
Q4 2018 101
Q3 2018 101
Q2 2018 101
Q1 2018 100
Q4 2017 91
Q3 2017 92
Q2 2017 88
Q1 2017 86
Q4 2016 86
Q3 2016 86
Q2 2016 86
Q1 2016 85
Q4 2015 84
Q3 2015 85
Q2 2015 84
Q1 2015 82
Q4 2014 74
Q3 2014 76
Q2 2014 76
Q1 2014 68
Q4 2013 62
Q3 2013 62
Q2 2013 62
Q1 2013 59
Q4 2012 50
Q3 2012 52
Q2 2012 51
Q1 2012 46
Q4 2011 42
Q3 2011 43
Q2 2011 42
Q1 2011 42
Q4 2010 42
Q3 2010 42
Q2 2010 42
Q1 2010 42
Q4 2009 42
Q3 2009 42
Q2 2009 42
Q1 2009 41
Q4 2008 41
Q3 2008 41
Q2 2008 41
Q1 2008 41
Q4 2007 39
Q3 2007 39
Q2 2007 38
Q1 2007 37
Q4 2006 32
Q3 2006 32
Q2 2006 32
Q1 2006 30
Q4 2005 22
Q3 2005 21
Q2 2005 21
Q1 2005 20
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $8.030B $0.075B
Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company developing novel therapeutics based on RNA interference, or RNAi. The company is applying its therapeutic expertise in RNAi to address significant medical needs, many of which cannot effectively be addressed with small molecules or antibodies, the current major classes of drugs. Alnylam is building a pipeline of RNAi therapeutics; its lead program is in Phase I human clinical trials for the treatment of respiratory syncytial virus infection, which is the leading cause of hospitalization in infants in the U.S. The company's leadership position in fundamental patents, technology, and know-how relating to RNAi has enabled it to form major alliances with leading companies including Merck, Medtronic, Novartis, and Biogen Idec.
Stock Name Country Market Cap PE Ratio
Amgen (AMGN) United States $108.806B 12.30
Gilead Sciences (GILD) United States $82.919B 10.07
Celgene (CELG) United States $63.614B 10.78
Biogen (BIIB) United States $44.842B 8.51
Vertex Pharmaceuticals (VRTX) United States $44.598B 53.91
Illumina (ILMN) United States $43.100B 49.95
CSL (CSLLY) Australia $35.794B 0.00
Regeneron Pharmaceuticals (REGN) United States $32.576B 15.31
Actelion (ALIOF) Switzerland $29.891B 0.00
Alexion Pharmaceuticals (ALXN) United States $27.088B 15.33
Incyte (INCY) United States $17.271B 70.04
Exact Sciences (EXAS) United States $14.835B 0.00
BioMarin Pharmaceutical (BMRN) United States $14.607B 0.00
SINO PHARMACEUT (SBMFF) China $14.154B 0.00
Seattle Genetics (SGEN) United States $12.140B 0.00
Sarepta Therapeutics (SRPT) United States $11.068B 0.00
Genmab (GNMSF) Denmark $11.046B 56.15
Array BioPharma (ARRY) United States $10.373B 0.00
Galapagos (GLPG) Belgium $9.396B 0.00
Bio-Rad Laboratories (BIO.B) United States $9.283B 49.21
QIAGEN (QGEN) Netherlands $8.917B 29.29
Guardant Health (GH) United States $8.158B 0.00
Bio-Techne Corp (TECH) United States $7.933B 54.13
Bluebird Bio (BLUE) United States $7.614B 0.00
Exelixis (EXEL) United States $6.419B 16.36
Amarin (AMRN) Ireland $5.979B 0.00
BeiGene (BGNE) Cayman Islands $5.801B 0.00
Ascendis Pharma (ASND) Denmark $4.841B 0.00
Blueprint Medicines (BPMC) United States $4.775B 0.00
ARGENX SE-ADR (ARGX) Netherlands $4.762B 0.00
Moderna (MRNA) United States $4.642B 0.00
Horizon Pharma Public (HZNP) Ireland $4.456B 11.48
Repligen (RGEN) United States $4.099B 102.12
Mirati Therapeutics (MRTX) United States $3.821B 0.00
Spark Therapeutics (ONCE) United States $3.720B 0.00
ACADIA Pharmaceuticals (ACAD) United States $3.705B 0.00
China Biologic Products (CBPO) China $3.661B 23.25
Alkermes (ALKS) Ireland $3.651B 0.00
Ultragenyx Pharmaceutical (RARE) United States $3.569B 0.00
MorphoSys AG (MOR) Germany $3.528B 0.00
Arena Pharmaceuticals (ARNA) United States $3.064B 6.23
Amicus Therapeutics (FOLD) United States $2.934B 0.00
Immunomedics (IMMU) United States $2.860B 0.00
UniQure (QURE) Netherlands $2.736B 0.00
Medicines (MDCO) United States $2.670B 0.00
Reata Pharmaceuticals (RETA) United States $2.620B 0.00
CRISPR Therapeutics AG (CRSP) Switzerland $2.595B 0.00
MyoKardia (MYOK) United States $2.466B 0.00
Halozyme Therapeutics (HALO) United States $2.370B 0.00
Nabriva Therapeutics AG (NBRV) Ireland $2.357B 0.00
NeoGenomics (NEO) United States $2.277B 149.06
Emergent Biosolutions (EBS) United States $2.269B 19.71
Ligand Pharmaceuticals (LGND) United States $2.233B 18.49
Acceleron Pharma (XLRN) United States $2.230B 0.00
Myriad Genetics (MYGN) United States $2.092B 20.81
Genomic Health (GHDX) United States $2.075B 44.07
Zai Lab (ZLAB) China $2.068B 0.00
Intercept Pharmaceuticals (ICPT) United States $2.044B 0.00
Akcea Therapeutics (AKCA) United States $2.041B 0.00
Denali Therapeutics (DNLI) United States $1.988B 0.00
REGENXBIO (RGNX) United States $1.800B 0.00
Insmed (INSM) United States $1.720B 0.00
Cambrex (CBM) United States $1.514B 19.15
AnaptysBio (ANAB) United States $1.474B 0.00
RA PHARMCTL INC (RARX) United States $1.418B 0.00
Fate Therapeutics (FATE) United States $1.393B 0.00
Innoviva (INVA) United States $1.361B 3.76
Sangamo Therapeutics (SGMO) United States $1.338B 0.00
Alector (ALEC) United States $1.298B 0.00
Athenex (ATNX) United States $1.278B 0.00
Coherus BioSciences (CHRS) United States $1.226B 0.00
Orchard Therapeutics (ORTX) United Kingdom $1.185B 0.00
Editas Medicine (EDIT) United States $1.174B 0.00
Epizyme (EPZM) United States $1.156B 0.00
Dicerna Pharmaceuticals (DRNA) United States $1.032B 0.00
Cara Therapeutics (CARA) United States $1.030B 0.00
Codexis (CDXS) United States $1.011B 0.00
Twist Bioscience (TWST) United States $0.982B 0.00
ANI Pharmaceuticals (ANIP) United States $0.973B 17.25
Zymeworks (ZYME) Canada $0.952B 0.00
Momenta Pharmaceuticals (MNTA) United States $0.947B 0.00
Principia Biopharma (PRNB) United States $0.921B 0.00
Adverum Biotechnologies (ADVM) United States $0.891B 0.00
ZIOPHARM Oncology Inc (ZIOP) United States $0.884B 0.00
Retrophin (RTRX) United States $0.879B 0.00
BAVARIAN NORDIC (BVNRY) Denmark $0.856B 0.00
Vericel (VCEL) United States $0.822B 0.00
Alder BioPharmaceuticals (ALDR) United States $0.820B 0.00
WAVE Life Sciences (WVE) Singapore $0.794B 0.00
Arvinas (ARVN) United States $0.789B 0.00
Intellia Therapeutics (NTLA) United States $0.782B 0.00
Precision BioSciences (DTIL) United States $0.701B 0.00
Zealand Pharma (ZEAL) Denmark $0.692B 8.08
Vanda Pharmaceuticals (VNDA) United States $0.688B 32.47
Zealand Pharma (ZLDPF) Denmark $0.683B 0.00
Intra-Cellular Therapies (ITCI) United States $0.652B 0.00
Cytokineticsorporated (CYTK) United States $0.643B 0.00
Cellectis S.A (CLLS) France $0.634B 0.00
Heska (HSKA) United States $0.622B 63.66
Autolus Therapeutics (AUTL) United Kingdom $0.612B 0.00
DBV Technologies S.A (DBVT) France $0.600B 0.00
Stemline Therapeutics (STML) United States $0.588B 0.00
Clovis Oncology (CLVS) United States $0.580B 0.00
Anika Therapeutics (ANIK) United States $0.577B 19.72
Lexicon Pharmaceuticals (LXRX) United States $0.561B 0.00
OXFORD BIOMEDCL (OXBDF) United Kingdom $0.560B 0.00
Revance Therapeutics (RVNC) United States $0.554B 0.00
CytomX Therapeutics (CTMX) United States $0.527B 0.00
Pharming Group (PHGUF) Netherlands $0.521B 0.00
MiMedx (MDXG) United States $0.503B 0.00
Mesoblast (MESO) Australia $0.494B 0.00
PHARMA MAR SA (PHMMF) Spain $0.452B 0.00
UROGEN PHARMA (URGN) United States $0.438B 0.00
Basilea Pharmaceutica AG (BPMUF) Switzerland $0.437B 0.00
Puma Biotechnology (PBYI) United States $0.394B 0.00
Prothena (PRTA) Ireland $0.393B 0.00
AC Immune SA (ACIU) Switzerland $0.378B 24.35
PDL BioPharma (PDLI) United States $0.376B 8.97
Biofrontera AG (BFRA) Germany $0.373B 0.00
Sinovac Biotech (SVA) China $0.371B 0.00
Arcus Biosciences (RCUS) United States $0.364B 0.00
Gritstone Oncology (GRTS) United States $0.361B 0.00
Starpharma Holdings (SPHRY) Australia $0.360B 0.00
Bellus Health (BLUSF) Canada $0.358B 0.00
Scholar Rock Holding (SRRK) United States $0.345B 0.00
Avid Bioservices (CDMO) United States $0.343B 0.00
Adaptimmune Therapeutics (ADAP) United Kingdom $0.342B 0.00
Merus (MRUS) Netherlands $0.341B 0.00
BioDelivery Sciences (BDSI) United States $0.341B 0.00
Albireo Pharma (ALBO) United States $0.340B 0.00
Acorda Therapeutics (ACOR) United States $0.332B 5.85
Agenus (AGEN) United States $0.330B 0.00
Achillion Pharmaceuticals (ACHN) United States $0.330B 0.00
Prometic Life Sciences (PFSCD) Canada $0.322B 0.00
Kadmon Holdings (KDMN) United States $0.321B 0.00
Theratechnologies (THERF) Canada $0.320B 0.00
Sorrento Therapeutics (SRNE) United States $0.319B 0.00
Syros Pharmaceuticals (SYRS) United States $0.314B 0.00
Protagonist Therapeutics (PTGX) United States $0.307B 0.00
Senesco Technologies (ELOX) United States $0.297B 0.00
AMAG Pharmaceuticals (AMAG) United States $0.295B 0.00
Cellular Biomedicine (CBMG) United States $0.277B 0.00
Inovio Pharmaceuticals (INO) United States $0.274B 0.00
Kindred Biosciences (KIN) United States $0.264B 0.00
Xenon Pharmaceuticals (XENE) Canada $0.258B 0.00
Sutro Biopharma (STRO) United States $0.256B 0.00
Syndax Pharmaceuticals (SNDX) United States $0.246B 0.00
PHASEBIO PHARMA (PHAS) United States $0.246B 0.00
ChromaDex (CDXC) United States $0.245B 0.00
Kamada (KMDA) Israel $0.239B 9.28
Dynavax Technologies (DVAX) United States $0.238B 0.00
Geron (GERN) United States $0.229B 0.00
Pieris Pharmaceuticals (PIRS) United States $0.225B 0.00
ADMA Biologics Inc (ADMA) United States $0.224B 0.00
Athersys (ATHX) United States $0.213B 0.00
Aeglea BioTherapeutics (AGLE) United States $0.202B 0.00
Five Prime Therapeutics (FPRX) United States $0.202B 0.00
MannKind (MNKD) United States $0.201B 0.00
Mersana Therapeutics (MRSN) United States $0.200B 0.00
Cerecor (CERC) United States $0.197B 0.00
Affimed (AFMD) Germany $0.193B 0.00
OSMOTICA PHARM (OSMT) United States $0.184B 0.00
POXEL SA FRANCE (PXXLF) $0.184B 0.00
Abeona Therapeutics (ABEO) United States $0.184B 0.00
Synlogic (SYBX) United States $0.179B 0.00
Enzo Biochem (ENZ) United States $0.174B 0.00
Spero Therapeutics (SPRO) United States $0.174B 0.00
Compugen (CGEN) Israel $0.172B 0.00
Arsanis (XFOR) United States $0.168B 0.00
Newron Pharmaceuticals SpA (NWPHF) $0.165B 0.00
XOMA (XOMA) United States $0.165B 0.00
Nicox SA (NICXF) France $0.161B 0.00
Cue Biopharma (CUE) United States $0.157B 0.00
EYEPOINT PHARMACEUTICALS, INC (EYPT) United States $0.156B 0.00
Strongbridge Biopharma (SBBP) United States $0.150B 8.66
Liquidia Technologies (LQDA) United States $0.144B 0.00
Celyad SA (CYAD) Belgium $0.142B 0.00
Alcobra (ARCT) United States $0.141B 0.00
OvaScience (MLND) United States $0.141B 0.00
Adocia (ADOCY) France $0.140B 0.00
Windtree Therapeutics (WINT) United States $0.138B 0.00
Dyadic (DYAI) United States $0.136B 0.00
TOCAGEN INC (TOCA) United States $0.135B 0.00
Northwest Biotherapeutics (NWBO) United States $0.130B 0.00
Seres Therapeutics (MCRB) United States $0.127B 0.00
Aptinyx (APTX) United States $0.125B 0.00
NantKwest (NK) United States $0.121B 0.00
AVEO Pharmaceuticals (AVEO) United States $0.114B 0.00
Aduro Biotech (ADRO) United States $0.114B 0.00
Nymox Pharmaceutical (NYMX) Canada $0.110B 0.00
Novavax (NVAX) United States $0.108B 0.00
Paratek Pharmaceuticals (PRTK) United States $0.108B 0.00
Verastem (VSTM) United States $0.106B 0.00
Checkpoint Therapeutics (CKPT) United States $0.104B 0.00
Menlo Therapeutics (MNLO) United States $0.103B 0.00
ASLAN Pharmaceuticals (ASLN) Singapore $0.103B 0.00
Catalyst Biosciences (CBIO) United States $0.099B 0.00
Arbutus Biopharma (ABUS) Canada $0.098B 0.00
SESEN BIO, INC (SESN) United States $0.098B 0.00
Trevena (TRVN) United States $0.094B 0.00
Fortress Biotech (FBIO) United States $0.089B 0.00
Pluristem Therapeutics (PSTI) Israel $0.088B 0.00
ANIXA BIOSCIENCES INC (ANIX) United States $0.087B 0.00
Spring Bank Pharmaceuticals (SBPH) United States $0.084B 0.00
Catabasis Pharmaceuticals (CATB) United States $0.082B 0.00
Aridis Pharmaceuticals (ARDS) United States $0.080B 0.00
Unum Therapeutics (UMRX) United States $0.079B 0.00
VBI Vaccines (VBIV) United States $0.079B 0.00
AquaBounty Technologies (AQB) United States $0.078B 0.00
Curis (CRIS) United States $0.076B 0.00
Selecta Biosciences (SELB) United States $0.076B 0.00
Merrimack Pharmaceuticals (MACK) United States $0.071B 0.00
Idera Pharmaceuticals (IDRA) United States $0.071B 0.00
Applied Genetic Technologies (AGTC) United States $0.071B 38.80
VTv Therapeutics (VTVT) United States $0.070B 0.00
Signal Genetics (MGEN) United States $0.070B 0.00
Orgenesis (ORGS) United States $0.067B 0.00
Oncobiologics (OTLK) United States $0.064B 0.00
Alimera Sciences (ALIM) United States $0.062B 0.00
Antibe Therapeutics (ATBPF) Canada $0.061B 0.00
ARAVIVE, INC (ARAV) United States $0.060B 0.00
NewLink Genetics (NLNK) United States $0.060B 0.00
Organovo Holdings (ONVO) United States $0.060B 0.00
Sunesis Pharmaceuticals (SNSS) United States $0.058B 0.00
Prima BioMed (IMMP) Australia $0.057B 0.00
AIT Therapeutics (XAIR) United States $0.057B 0.00